Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. METHODS: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. RESULTS: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r = -0.84, P<0.001). CONCLUSIONS: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
The Eating Attitudes Test: an index of the symptoms of anorexia nervosa
Garner, D. M., & Garfinkel, P. E. (1979) · Psychological Medicine · doi:10.1017/s0033291700030762 · Cited by 3,543 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationPlasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationObesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Cited by
Taheri, S., Lin, L., Austin, D., Young, T., & Mignot, E. (2004) · PLoS Medicine · doi:10.1371/journal.pmed.0010062 · Cited by 2,477
“appetite regulatory hormones, such as PYY 3–36 [28], were not measured.”
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Overweight in Children and Adolescents: Pathophysiology, Consequences, Prevention, and Treatment
Daniels, S. R., Arnett, D. K., Eckel, R. H., Gidding, S. S., Hayman, L. L., Kumanyika, S., Robinson, T. N., Scott, B. J., St. Jeor, S., & Williams, C. L. (2005) · Circulation · doi:10.1161/01.cir.0000161369.71722.10 · Cited by 1,550
Chambers, E. S., Viardot, A., Psichas, A., Morrison, D. J., Murphy, K. G., Zac-Varghese, S. E. K., MacDougall, K., Preston, T., Tedford, C., Finlayson, G. S., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307913 · Cited by 1,424
“25 27 In this study, the rise in PYY and GLP-1 was apparent between 240 min and 420 min following oral administration of the inulin-propionate ester, and reached levels similar to those observed following a 1000 kcal meal.”
MethodSelf-citationGastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216
Flier, J. S. (2004) · Cell · doi:10.1016/s0092-8674(03)01081-x · Cited by 1,112
Slavin, J. L. (2005) · Nutrition · doi:10.1016/j.nut.2004.08.018 · Cited by 1,074
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Roux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985
“Following RYGB, postprandial PYY concentrations were elevated to levels previously shown to have appetite-reducing effects.(19,20) We propose that the higher postprandial PYY response after gastric bypass surgery due to the altered intestinal anatomy may contribute to the patients’ increased satiety and weight loss.”
BackgroundSelf-citationMulticenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Karamanakos, S. N., Vagenas, K., Kalfarentzos, F., & Alexandrides, T. K. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318156f012 · Cited by 813
“Intravenous infusion of PYY3–36 in humans induces satiety and reduces food intake.(19,20) Recent studies have shown depressed PYY levels in morbidly obese individuals in comparison to lean controls and blunted response in PYY release after meal stimulation.”
BackgroundImpact of insufficient sleep on total daily energy expenditure, food intake, and weight gain
Markwald, R. R., Melanson, E. L., Smith, M. R., Higgins, J., Perreault, L., Eckel, R. H., & Wright, K. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216951110 · Cited by 810
Obesity-Associated Hypertension: New Insights Into Mechanisms
Rahmouni, K., Correia, M. L. G., Haynes, W. G., & Mark, A. L. (2005) · Hypertension · doi:10.1161/01.hyp.0000151325.83008.b4 · Cited by 784
Gut hormones and the regulation of energy homeostasis
Murphy, K. G., & Bloom, S. R. (2006) · Nature · doi:10.1038/nature05484 · Cited by 778
“Obese humans show normal sensitivity to the anorectic effects of PYY 3–36 , and circulating levels of PYY are not raised in the obese, in contrast to leptin level”
BackgroundSelf-citationThe human gut microbiota: Metabolism and perspective in obesity
Gomes, A. C., Hoffmann, C., & Mota, J. F. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1465157 · Cited by 727
“Batterham et al.(73) found a 30% reduction in food intake 90 minutes after the infusion of PYY3–36 in obese individuals, a value similar to eutrophic patients.”
ResultGut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
le Roux, C. W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., Lönroth, H., Fändriks, L., Ghatei, M. A., Bloom, S. R., et al. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180caa3e3 · Cited by 741
Self-citationFunction and mechanisms of enteroendocrine cells and gut hormones in metabolism
Gribble, F. M., & Reimann, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0168-8 · Cited by 670
Neuroendocrine control of food intake
Valassi, E., Scacchi, M., & Cavagnini, F. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.06.004 · Cited by 645
“Notably, the reduction of caloric intake observed in obese patients following infusion of PYY3e36 is accompanied by a decrease in circulating ghrelin [25].”
BackgroundInfluentialCritical role for peptide YY in protein-mediated satiation and body-weight regulation
Batterham, R. L., Heffron, H., Kapoor, S., Chivers, J. E., Chandarana, K., Herzog, H., Le Roux, C. W., Thomas, E. L., Bell, J. D., & Withers, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.08.001 · Cited by 626
Self-citationHavel, P. J. (2005) · Nutrition Reviews · doi:10.1111/j.1753-4887.2005.tb00132.x · Cited by 607
Ghrelin?a hormone with multiple functions
KORBONITS, M. (2004) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2004.03.002 · Cited by 595
Endocrine disrupters as obesogens
Grün, F., & Blumberg, B. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.02.018 · Cited by 582
“Cholecystokinin (CCK), glucagon-like peptide 1, peptide YY, insulin, leptin, and pro-opiomelanocortin (POMC)-derived peptides are effective satiety signals when administered centrally or promote obesity when absent [1, 109-115].”
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
“4) In the one comparison of PYY(3– 36)’s eating-inhibitory effect in obese and healthy-weight subjects to date, no difference was detected (61).”
BackgroundResultInfluentialPeterli, R., Wölnerhanssen, B., Peters, T., Devaux, N., Kern, B., Christoffel-Courtin, C., Drewe, J., von Flüe, M., & Beglinger, C. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181ae32e3 · Cited by 565
“In healthy subjects, peak concentrations of PYY are obtained postprandially; in addition, exogenous administration of PYY3-36 induces a dosedependent loss of appetite, both in healthy volunteers and in obese persons, suggesting that the peptide acts as a satiety factor.(34,35) Whether the increase observed both in our…”
BackgroundAttenuated Peptide YY Release in Obese Subjects Is Associated with Reduced Satiety
le Roux, C. W., Batterham, R. L., Aylwin, S. J. B., Patterson, M., Borg, C. M., Wynne, K. J., Kent, A., Vincent, R. P., Gardiner, J., Ghatei, M. A., et al. (2006) · Endocrinology · doi:10.1210/en.2005-0972 · Cited by 552
Self-citationBeta Glucan: Health Benefits in Obesity and Metabolic Syndrome
El Khoury, D., Cuda, C., Luhovyy, B. L., & Anderson, G. H. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/851362 · Cited by 538
“Similarly, it decreased appetite and food intake both in lean and obese humans [269, 270].”
BackgroundThe gut and energy balance: visceral allies in the obesity wars
Badman, M. K., & Flier, J. S. (2005) · Science · doi:10.1126/science.1109951 · Cited by 532
Biomarkers of satiation and satiety
de Graaf, C., Blom, W. A., Smeets, P. A., Stafleu, A., & Hendriks, H. F. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.6.946 · Cited by 519
“Subjective ratings of hunger and satiety were in line with the lower food intake (57, 193).”
BackgroundResultInfluentialSuglia, S. F., Koenen, K. C., Boynton-Jarrett, R., Chan, P. S., Clark, C. J., Danese, A., Faith, M. S., Goldstein, B. I., Hayman, L. L., Isasi, C. R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000536 · Cited by 518
Gastric Bypass for Obesity: Mechanisms of Weight Loss and Diabetes Resolution
Cummings, D. E., Overduin, J., & Foster-Schubert, K. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0433 · Cited by 503
Neuropeptide, Y, peptide YY and pancreatic polypeptide in the gut-brain axis
Holzer, P., Reichmann, F., & Farzi, A. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.08.005 · Cited by 501
Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes
Wang, X., Ota, N., Manzanillo, P., Kates, L., Zavala-Solorio, J., Eidenschenk, C., Zhang, J., Lesch, J., Lee, W. P., Ross, J., et al. (2014) · Nature · doi:10.1038/nature13564 · Cited by 500
PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans
Batterham, R. L., ffytche, D. H., Rosenthal, J. M., Zelaya, F. O., Barker, G. J., Withers, D. J., & Williams, S. C. R. (2007) · Nature · doi:10.1038/nature06212 · Cited by 484
Self-citationBariatric Surgery: A Review of Procedures and Outcomes
Elder, K. A., & Wolfe, B. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.057 · Cited by 470
Central Control of Body Weight and Appetite
Woods, S. C., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1630 · Cited by 458
“Fasting and postprandial levels of PYY are lower in obese adults compared with lean controls (105, 106).”
BackgroundIleal brake: a sensible food target for appetite control. A review
Maljaars, P. W. J., Peters, H. P. F., Mela, D. J., & Masclee, A. A. M. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.07.018 · Cited by 451
“demonstrated in humans that intravenous infusions replicating postprandial PYY3–36 concentrations lessened hunger and decreased ad libitum food intake by 36%, without causing nausea, affecting food palatability or altering fluid intake [65,66].”
BackgroundRole of neuropeptides in appetite regulation and obesity – A review
Arora, S., & Anubhuti (2006) · Neuropeptides · doi:10.1016/j.npep.2006.07.001 · Cited by 455
“Obese human subjects have a relatively low circulating PYY and a relative deficiency of post-prandial secretion (Renshaw and Batterham, 2005; Batterham et al., 2003), although these subjects retain sensitivity to exogenous administration.”
BackgroundGastrointestinal hormones and food intake
Strader, A. D., & Woods, S. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.10.043 · Cited by 447
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
“, sterile for culture and negative for pyrogen, as previously described (10).”
BackgroundSelf-citationGut Hormones and Appetite Control
Wren, A. M., & Bloom, S. R. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.048 · Cited by 432
Self-citationThe role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats
Koda, S., Date, Y., Murakami, N., Shimbara, T., Hanada, T., Toshinai, K., Niijima, A., Furuya, M., Inomata, N., Osuye, K., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1266 · Cited by 431
“In human studies, plasma PYY3–36 levels of normal subjects rise immediately after a meal (6, 35), suggesting that PYY3–36 may be involved in the short-term feeding control rather than long-term regulation of body fat mass.”
BackgroundLong-Term Impact of Bariatric Surgery on Body Weight, Comorbidities, and Nutritional Status
Shah, M., Simha, V., & Garg, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0557 · Cited by 433
Korner, J., Bessler, M., Cirilo, L. J., Conwell, I. M., Daud, A., Restuccia, N. L., & Wardlaw, S. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1076 · Cited by 417
“To date, however, the only studies in humans show that peripheral administration of PYY(3–36) decreases food intake (21, 22).”
BackgroundInfluentialMorínigo, R., Moizé, V., Musri, M., Lacy, A. M., Navarro, S., Marín, J. L., Delgado, S., Casamitjana, R., & Vidal, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0904 · Cited by 397
“Peripherally administered GLP-1 and PYY elicit satiety in healthy (15, 16) and obese subjects (15, 17).”
BackgroundResultGhrelin increases food intake in obese as well as lean subjects
Druce, M. R., Wren, A. M., Park, A. J., Milton, J. E., Patterson, M., Frost, G., Ghatei, M. A., Small, C., & Bloom, S. R. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0803001 · Cited by 397
Self-citationEnteroendocrine cells: a review of their role in brain–gut communication
Latorre, R., Sternini, C., De Giorgio, R., & Greenwood‐Van Meerveld, B. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12754 · Cited by 392
The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release
Martin, A. M., Sun, E. W., Rogers, G. B., & Keating, D. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00428 · Cited by 384
Pournaras, D. J., Glicksman, C., Vincent, R. P., Kuganolipava, S., Alaghband-Zadeh, J., Mahon, D., Bekker, J. H. R., Ghatei, M. A., Bloom, S. R., Walters, J. R. F., et al. (2012) · Endocrinology · doi:10.1210/en.2011-2145 · Cited by 383
“PYY-like immunoreactivity was measured with a specific and sensitive RIA, which measures both the full length (PYY1-36) and the fragment (PYY3-36) (32).”
MethodSelf-citationA link between FTO, ghrelin, and impaired brain food-cue responsivity
Karra, E., O’Daly, O. G., Choudhury, A. I., Yousseif, A., Millership, S., Neary, M. T., Scott, W. R., Chandarana, K., Manning, S., Hess, M. E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci44403 · Cited by 381
“Circulating levels of the orexigenic hormone, acyl-ghrelin, and the satiety hormone, peptide YY3-36 (PYY3-36), alter appetite, food intake (34–36), and modulate brain activity within both homeostatic and reward-related brain regions (33, 37–39).”
Self-citationEnteroendocrine cells: a site of 'taste' in gastrointestinal chemosensing
Sternini, C., Anselmi, L., & Rozengurt, E. (2008) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3282f43a73 · Cited by 377
“There has been increasing interest in PYY3–36 for its inhibition of food intake and induction of aversive food response [13,14], even though there are controversies about the food intake effect [15].”
BackgroundGut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
Silva, A. D., & Bloom, S. R. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.1.10 · Cited by 373
“A similar study administered a 90 minute intravenous infusion of PYY3-36 to lean and overweight human subjects at a dose of 0.8 pmol/kg/min, with 19% reduction in ad libitum food intake at a buffet meal served 2 hours after completion of the infusion.39 However, in contrast to the studies by Batterham et al., signific…”
BackgroundMethodInfluentialSelf-citationHormonal regulation of food intake
Stanley, S., Wynne, K., McGowan, B., & Bloom, S. (2005) · Physiological Reviews · doi:10.1152/physrev.00015.2004 · Cited by 372
“However, peripheral administration of PYY3–36 also reduces plasma ghrelin levels (31), which may contribute to its anorectic effect.”
BackgroundSelf-citationPeptide YY3–36 and Glucagon-Like Peptide-17–36 Inhibit Food Intake Additively
Neary, N. M., Small, C. J., Druce, M. R., Park, A. J., Ellis, S. M., Semjonous, N. M., Dakin, C. L., Filipsson, K., Wang, F., Kent, A. S., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0237 · Cited by 371
“• PYY and GLP-1 Inhibit Feeding Additively Endocrinology, December 2005, 146(12):5120–5127 5123”
BackgroundInfluentialSelf-citationChallis, B. G., Coll, A. P., Yeo, G. S. H., Pinnock, S. B., Dickson, S. L., Thresher, R. R., Dixon, J., Zahn, D., Rochford, J. J., White, A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306931101 · Cited by 371
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363
Self-citationEffect of Peptide YY3–36 on Food Intake in Humans
Degen, L., Oesch, S., Casanova, M., Graf, S., Ketterer, S., Drewe, J., & Beglinger, C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.001 · Cited by 366
Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update
Vanholder, R., Pletinck, A., Schepers, E., & Glorieux, G. (2018) · Toxins · doi:10.3390/toxins10010033 · Cited by 356
“Peptide YY is an anorexigen [469,470] and inhibitor of gastric motility [471].”
BackgroundGastrointestinal hormones regulating appetite
Chaudhri, O., Small, C., & Bloom, S. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1856 · Cited by 346
“Similarly, infusion intravenously into lean humans resulted in a decrease in appetite that persisted and was reflected in reduced food intake recorded in food diaries 24 hours after the infusion (Batterham et al. 2003b).”
BackgroundResultInfluentialSelf-citationThe role of proopiomelanocortin (POMC) neurones in feeding behaviour
Millington, G. W. (2007) · Nutrition & Metabolism · doi:10.1186/1743-7075-4-18 · Cited by 345
“After a meal, the gut releases PYY3–36 into the circulation, which crosses the BBB and reduces food intake by suppressing NPY release and increasing POMC release in the arcuate nucleus [77-80].”
BackgroundJacobsen, S. H., Olesen, S. C., Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Worm, D., Almdal, T., Naver, L. S., Hvolris, L. E., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0621-4 · Cited by 342
“Similar to GLP-1 [16], PYY promotes satiety [54] and is released from the L cells [55].”
BackgroundControl of appetite and energy intake by SCFA: what are the potential underlying mechanisms?
Chambers, E. S., Morrison, D. J., & Frost, G. (2015) · Proceedings of the Nutrition Society · doi:10.1017/s0029665114001657 · Cited by 342
“Intravenous infusion of PYY to both lean and obese human subjects has been demonstrated to reduce energy intake((41,42)), and this anorexigenic effect is thought be exerted via neuropeptide Y inhibition and POMC activation in the hypothalamic ARC((41,43)).”
BackgroundSelf-citationSatiation, satiety and their effects on eating behaviour
Benelam, B. (2009) · Nutrition Bulletin · doi:10.1111/j.1467-3010.2009.01753.x · Cited by 340
The role of peptide YY in appetite regulation and obesity
Karra, E., Chandarana, K., & Batterham, R. L. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.164269 · Cited by 336
“went on to evaluate the effects of infusing PYY3–36 on caloric intake in lean and obese male and female subjects and found that obese subjects remained sensitive to the anorectic actions of PYY3–36 (Batterham et al. 2003).”
BackgroundSelf-citationWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal ef fi cacy with poor tolerability [94].”
InfluentialCanfora, E. E., van der Beek, C. M., Jocken, J. W. E., Goossens, G. H., Holst, J. J., Olde Damink, S. W. M., Lenaerts, K., Dejong, C. H. C., & Blaak, E. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-02546-x · Cited by 331
How Palatable Food Disrupts Appetite Regulation
Erlanson‐Albertsson, C. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_179.x · Cited by 330
“Peptide YY infusion also caused a significant decrease in the cumulative 24 hr caloric intake in both obese and lean subjects, suggesting that obese subjects were sensitive to the peptide YY action (Batterham et al. 2003).”
BackgroundBroom, D. R., Batterham, R. L., King, J. A., & Stensel, D. J. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90706.2008 · Cited by 321
“The majority of studies examining circulating PYY have reported total PYY levels using assays which detect both the PYY1-36 and PYY3-36 ( 5 , 34, 35, 37, 38).”
BackgroundSelf-citationThe role of gut hormones and the hypothalamus in appetite regulation
Suzuki, K., Simpson, K. A., Minnion, J. S., Shillito, J. C., & Bloom, S. R. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-077 · Cited by 319
Self-citationSeven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells
Engelstoft, M. S., Park, W.-M., Sakata, I., Kristensen, L. V., Husted, A. S., Osborne-Lawrence, S., Piper, P. K., Walker, A. K., Pedersen, M. H., Nøhr, M. K., et al. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.08.006 · Cited by 323
“The peptide hormones PYY and pancreatic polypeptide (PP) acting through Y2 and Y4 receptors, respectively both efficiently decrease plasma ghrelin in vivo [25,115].”
BackgroundInfluentialBorg, C. M., le Roux, C. W., Ghatei, M. A., Bloom, S. R., Patel, A. G., & Aylwin, S. J. B. (2006) · British Journal of Surgery · doi:10.1002/bjs.5227 · Cited by 318
Self-citationThe GRAFS classification system of G-protein coupled receptors in comparative perspective
Schiöth, H. B., & Fredriksson, R. (2005) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2004.12.018 · Cited by 313
Obesity‐related leptin regulates Alzheimer's Aβ
Fewlass, D. C., Noboa, K., Pi‐Sunyer, F. X., Johnston, J. M., Yan, S. D., & Tezapsidis, N. (2004) · The FASEB Journal · doi:10.1096/fj.04-2572com · Cited by 308
Talsania, T., Anini, Y., Siu, S., Drucker, D. J., & Brubaker, P. L. (2005) · Endocrinology · doi:10.1210/en.2005-0473 · Cited by 306
Effects of Resistant Starch, A Non‐digestible Fermentable Fiber, on Reducing Body Fat
Keenan, M. J., Zhou, J., McCutcheon, K. L., Raggio, A. M., Bateman, H. G., Todd, E., Jones, C. K., Tulley, R. T., Melton, S., Martin, R. J., et al. (2006) · Obesity · doi:10.1038/oby.2006.176 · Cited by 302
“Unlike leptin, PYY has been shown to be effective in reducing food intake in obese humans (20) and adiposity in obese mice (22).”
BackgroundTreatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Strader, A. D., Vahl, T. P., Jandacek, R. J., Woods, S. C., D’Alessio, D. A., & Seeley, R. J. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00153.2004 · Cited by 291
“Several of these intestinal hormones, such as glucagon-like peptide-1 (GLP-1) and peptide tyrosine-tyrosine [PYY-(3–36)], have anorectic effects (5, 6, 16, 45, 47).”
BackgroundGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“Recently, a marked inhibition of food intake in obese subjects was reported during the administration of peptide YY (3–36) [273].”
BackgroundStock, S., Leichner, P., Wong, A. C. K., Ghatei, M. A., Kieffer, T. J., Bloom, S. R., & Chanoine, J.-P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1251 · Cited by 281
Self-citationExpression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin
Burdyga, G., Lal, S., Varro, A., Dimaline, R., Thompson, D. G., & Dockray, G. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5404-03.2004 · Cited by 280
“…be influenced by circulating satiety factors, e.g., leptin from adipose tissue and PYY from the gastrointestinal tract, as well as orexigenic factors, e.g., ghrelin from gastric endocrine (X-) cells (Kojima et al., 1999; Schwartz et al., 2000; Broberger and Hokfelt, 2001; Batterham et al., 2003).”
InfluentialFreeland, K. R., & Wolever, T. M. S. (2010) · British Journal of Nutrition · doi:10.1017/s0007114509991863 · Cited by 275
Obesity: The Integrated Roles of Environment and Genetics
Speakman, J. R. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.8.2090s · Cited by 273
Colocalization of the α-subunit of gustducin with PYY and GLP-1 in L cells of human colon
Rozengurt, N., Wu, S. V., Chen, M. C., Huang, C., Sternini, C., & Rozengurt, E. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00074.2006 · Cited by 271
“the colon, are characterized by the production of peptide YY (PYY), a peptide that is attracting considerable attention because the peripheral administration of the PYY3–36 form of PYY (27) reduced food intake in mice, rats, and humans (4, 5) and, like bitter stimuli, evoked an aversive food response in mice (20).”
BackgroundThe effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones
Meek, C. L., Lewis, H. B., Reimann, F., Gribble, F. M., & Park, A. J. (2016) · Peptides · doi:10.1016/j.peptides.2015.08.013 · Cited by 269
Juvonen, K. R., Purhonen, A.-K., Salmenkallio-Marttila, M., Lähteenmäki, L., Laaksonen, D. E., Herzig, K.-H., Uusitupa, M. I. J., Poutanen, K. S., & Karhunen, L. J. (2009) · The Journal of Nutrition · doi:10.3945/jn.108.099945 · Cited by 264
Energy Homeostasis, Obesity and Eating Disorders: Recent Advances in Endocrinology
Gale, S. M., Castracane, V. D., & Mantzoros, C. S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.2.295 · Cited by 265
Cephalic phase responses and appetite: Nutrition Reviews©, Vol. 68, No. 11
Smeets, P. A., Erkner, A., & De Graaf, C. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00334.x · Cited by 260
Active Ghrelin Levels and Active to Total Ghrelin Ratio in Cancer-Induced Cachexia
Garcia, J. M., Garcia-Touza, M., Hijazi, R. A., Taffet, G., Epner, D., Mann, D., Smith, R. G., Cunningham, G. R., & Marcelli, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1788 · Cited by 260
Sobrino Crespo, C., Perianes Cachero, A., Puebla Jiménez, L., Barrios, V., & Arilla Ferreiro, E. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00058 · Cited by 256
“A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.”
BackgroundMethodChowdhury, E. A., Richardson, J. D., Holman, G. D., Tsintzas, K., Thompson, D., & Betts, J. A. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.122044 · Cited by 255
“Obese individuals are more receptive to external cues to eat (25, 26) and display delayed satiation (27), possibly in part because of reduced concentrations of the satiety hormone peptide YY (28) and limited feedinginduced suppression of the orexigenic hormone ghrelin (29, 30).”
BackgroundGreenfield, J. R., Farooqi, I. S., Keogh, J. M., Henning, E., Habib, A. M., Blackwood, A., Reimann, F., Holst, J. J., & Gribble, F. M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26362 · Cited by 256
Gut hormones in the control of appetite
Murphy, K. G., & Bloom, S. R. (2004) · Experimental Physiology · doi:10.1113/expphysiol.2004.027789 · Cited by 250
“Recent evidence has shown that gut hormones administered at physiological concentrations can influence appetite in rodent models and humans (Wren et al. 2001a; Batterham et al. 2002, 2003b; Cohen et al. 2003).”
BackgroundInfluentialSelf-citationAcute Exercise and Hormones Related to Appetite Regulation: A Meta-Analysis
Schubert, M. M., Sabapathy, S., Leveritt, M., & Desbrow, B. (2014) · Sports Medicine · doi:10.1007/s40279-013-0120-3 · Cited by 249
“The same holds true for anorexigenic appetite hormones, although it is known that obese individuals have lower circulating PYY levels and appear to have a deficiency in postprandial secretion [61].”
Elevated Peptide YY Levels in Adolescent Girls with Anorexia Nervosa
Misra, M., Miller, K. K., Tsai, P., Gallagher, K., Lin, A., Lee, N., Herzog, D. B., & Klibanski, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1878 · Cited by 249
“• Elevated PYY Levels in Adolescent Girls with AN J Clin Endocrinol Metab, March 2006, 91(3):1027–1033 1029”
BackgroundMethodResultInfluentialIntegrated Upper Gastrointestinal Response to Food Intake
Camilleri, M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.023 · Cited by 247
The Role of the Autonomic Nervous System in the Pathophysiology of Obesity
Guarino, D., Nannipieri, M., Iervasi, G., Taddei, S., & Bruno, R. M. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00665 · Cited by 242
“PYY plasma concentrations are lower in obese in comparison to lean individuals either in the fasting period (Batterham et al., 2003) or in the post-prandial period (le Roux et al., 2006).”
BackgroundSloth, B., Holst, J. J., Flint, A., Gregersen, N. T., & Astrup, A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00450.2006 · Cited by 246
“8 pmol kg 1 min 1 and amounted to a decrease of between 25 and 34%, with the highest reduction in lean subjects (4, 5, 8, 18) and a somewhat lower reduction in obese subjects (4).”
BackgroundMethodResultInfluentialGut Peptides in the Regulation of Food Intake and Energy Homeostasis
Murphy, K. G., Dhillo, W. S., & Bloom, S. R. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0028 · Cited by 245
“We have found that doses of PYY3–36 that result in circulating levels of PYY within the physiological range reduce food intake in humans without causing nausea or any other ill effects (5, 6).”
BackgroundSelf-citationAcute effects of PYY3–36 on food intake and hypothalamic neuropeptide expression in the mouse
Challis, B. G., Pinnock, S. B., Coll, A. P., Carter, R. N., Dickson, S. L., & O’Rahilly, S. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.089 · Cited by 244
Differential Effects of Gastric Bypass and Banding on Circulating Gut Hormone and Leptin Levels
Korner, J., Inabnet, W., Conwell, I. M., Taveras, C., Daud, A., Olivero‐Rivera, L., Restuccia, N. L., & Bessler, M. (2006) · Obesity · doi:10.1038/oby.2006.179 · Cited by 240
“lower fasting levels of PYY compared with lean subjects (21,42), we and others (43) have not demonstrated this difference, suggesting that the postprandial change in PYY concentration may be of greater physiological importance than fasting levels.”
BackgroundPsichas, A., Reimann, F., & Gribble, F. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76309 · Cited by 243
“The effects of other gut hormones on ghrelin release are varied (95–97).”
Background
Metadata
- Authors
- Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 941-948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170277935
- Cited by
- 1,604
- References
- 27
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 31 · 2023: 29 · 2022: 33 · 2021: 54 · 2020: 40 · 2019: 63 · 2018: 44 · 2017: 61 · 2016: 61 · 2015: 60 · 2014: 78 · 2013: 83 · 2012: 89
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- PYY3-36, peptide YY, obesity, dietary intake, appetite, ghrelin, leptin resistance, gastrointestinal hormones, hypothalamic regulation of appetite, body mass index, energy intake
- MeSH terms
- Appetite, Double-Blind Method, Eating, Female, Humans, Insulin, Male, Obesity, Peptide Fragments, Cross-Over Studies, Peptide YY, Leptin, Peptide Hormones, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.